Satrajit Roychoudhury

Author

Pfizer (United States)ORCID

Also Known As

Enas, Nathan, Jaap Reijneveld, Roychoudhury, Satrajit, S Roychoudhury, S. Roychoudhury, Satrajit Roychoudhury

Publications

17.1K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)Novartis (Switzerland)Merck & Co., Inc., Rahway, NJ, USA (United States)Novartis (United States)Johns Hopkins University

About

Satrajit Roychoudhury is an author at Pfizer (United States) specializing in medicine, statistics, and biostatistics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	452
2	Public Health	5	5	547
3	Biostatistics	5	5	694
4	Health Sciences	3	3	121
5	Engineering	1	1	162

Satrajit Roychoudhury

Publications

16.2K

Citations

H-Index

Page 1

	Year	Citations
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Fernando P. Polack, Stephen J. Thomas, Nicholas Kitchin, New England Journal of Medicine	2020	15.1K
Robust meta‐analytic‐predictive priors in clinical trials with historical control information Heinz Schmidli, Sandro Gsteiger, Satrajit Roychoudhury, Biometrics Bayesian StatisticBayesian StatisticsMeta-analysisStandard PriorsHistorical Control Information	2014	436
Robust exchangeability designs for early phase clinical trials with multiple strata Beat Neuenschwander, Simon Wandel, Satrajit Roychoudhury, Pharmaceutical Statistics Robust Exchangeability DesignsEngineeringClinical EndpointRare Event EstimationBayesian Inference	2015	162
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine Stephen J. Thomas, Edson Duarte Moreira, Nicholas Kitchin, ImmunologyµG Bnt162b2Covid-19Cross-protectionVaccine Surveillance	2021	143
On the Use of Co-Data in Clinical Trials Beat Neuenschwander, Satrajit Roychoudhury, Heinz Schmidli Statistics in Biopharmaceutical Research Clinical EndpointActual TrialPhase Iii TrialsClinical TrialsRandomized Controlled Trial	2016	51
Robust Design and Analysis of Clinical Trials With Nonproportional Hazards: A Straw Man Guidance From a Cross-Pharma Working Group Satrajit Roychoudhury, Keaven M. Anderson, Jiabu Ye, Statistics in Biopharmaceutical Research Straw Man ProposalClinical EndpointRiskbenefit RatioStraw Man GuidanceClinical Trials	2021	51
Alternative Analysis Methods for Time to Event Endpoints Under Nonproportional Hazards: A Comparative Analysis Ray Lin, Ji Lin, Satrajit Roychoudhury, Figshare	2020	45
A Tutorial on Modern Bayesian Methods in Clinical Trials Natalia Muehlemann, Tianjian Zhou, Rajat Mukherjee, Therapeutic Innovation & Regulatory Science Bayesian StatisticBayesian StatisticsBayesian ModelingBiostatisticsBayesian Methods	2023	34
Bayesian leveraging of historical control data for a clinical trial with time‐to‐event endpoint Satrajit Roychoudhury, Beat Neuenschwander Statistics in Medicine	2020	28
Beyond<i>p</i>-values: A phase II dual-criterion design with statistical significance and clinical relevance Satrajit Roychoudhury, Nicolas Scheuer, Beat Neuenschwander Clinical Trials	2018	27

Page 1